Pharma News
-
Ulotaront hydrochloride by Sumitomo Pharma America for Schizophrenia: Likelihood of Approval
Ulotaront hydrochloride is under clinical development by Sumitomo Pharma America and currently in Phase III for Schizophrenia. Source link #Ulotaront…
Read More » -
Ulotaront hydrochloride by Sumitomo Pharma America for Generalized Anxiety Disorder (GAD): Likelihood of Approval
Ulotaront hydrochloride is under clinical development by Sumitomo Pharma America and currently in Phase III for Generalized Anxiety Disorder (GAD).…
Read More » -
Denosumab biosimilar by Sandoz Group for Bone Metastasis: Likelihood of Approval
Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Bone Metastasis. Source link #Denosumab #biosimilar…
Read More » -
Denosumab biosimilar by Sandoz Group for Post Menopausal Osteoporosis: Likelihood of Approval
Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Post Menopausal Osteoporosis. Source link #Denosumab…
Read More » -
Denosumab biosimilar by Sandoz Group for Humoral Hypercalcemia of Malignancy: Likelihood of Approval
Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Humoral Hypercalcemia of Malignancy. Source link…
Read More » -
Denosumab biosimilar by Sandoz Group for Giant Cell Tumor Of Bone: Likelihood of Approval
Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Giant Cell Tumor Of Bone. Source…
Read More » -
Denosumab biosimilar by Celltrion for Osteoporosis: Likelihood of Approval
Denosumab biosimilar is under clinical development by Celltrion and currently in Phase I for Osteoporosis. Source link #Denosumab #biosimilar #Celltrion…
Read More » -
Denosumab biosimilar by Sandoz Group for Giant Cell Tumor Of Bone: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of…
Read More » -
Denosumab biosimilar by Celltrion for Osteoporosis: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of…
Read More » -
Odevixibat by Ipsen for Biliary Atresia: Likelihood of Approval
Odevixibat is under clinical development by Ipsen and currently in Phase III for Biliary Atresia. Source link #Odevixibat #Ipsen #Biliary…
Read More »